低剂量阿哌沙班在HeartMate 3左心室辅助装置患者中的随机对照试验中期分析
无事件生存率两组相似(HR 1.46,95%CI 0.64-3.35,P=0.4)。阿哌沙班组出血率低于大型国际研究报道且无血栓增加,提示低剂量阿哌沙班可能平衡出血与抗凝疗效,但为初步假设生成结果。
要点
- 稳定HeartMate 3患者中,阿哌沙班2.5 mg每日两次与VKA的无事件生存率相似。
- 阿哌沙班组出血率低于大型国际研究报道,且未增加血栓事件。
- 结果为初步假设生成,需完整随访验证。
核心结论
- 阿哌沙班2.5 mg每日两次在稳定HeartMate 3患者中可能提供出血风险与抗凝疗效之间的有效平衡,但属初步假设生成结论。
研究设计与样本
- ApixiVAD研究为1:1随机、开放标签先导试验,比较减剂量阿哌沙班(2.5 mg每日两次)与标准VKA。
- 中位年龄55岁(50-64),女性6例(14%),LVAD植入至随机中位时间6个月(5-8),随访中位6个月(2-8)。
主要发现
- 无事件生存率两组相似(HR 1.46,95%CI 0.64-3.35,P=0.4,Cox模型)。
- 移植时血制品使用两组相似。
关键数值与推荐
- 阿哌沙班组出血率低于大型国际研究报道,且无血栓增加。
临床怎么用
- 对于TTR>60%的稳定HeartMate 3患者,低剂量阿哌沙班可能作为VKA的替代选择,但需进一步研究确认。
局限性
- 中期结果在招募结束后但未全部完成随访时获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular assist devices (LVADs) improve outcomes in advanced heart failure but require anticoagulation. Vitamin K antagonists (VKAs) have significant limitations, with labile international normalized ratios and suboptimal time in therapeutic range (TTR), associated with increased morbidity and mortality. Direct oral anticoagulant therapy has been contraindicated in LVAD patients. METHODS: The ApixiVAD study, a 1:1 randomized, open-label pilot trial, compared the reduced-dose apixaban (2.5 mg twice daily) with standard VKAs in stable HeartMate 3 patients with TTR > 60%. Aspirin was not mandated. Primary outcomes included thromboembolic events, bleeding, and death. RESULTS: Forty-four patients were randomized, 21 to apixaban and 23 to VKA. Median age was 55 years (50-64), and 6 were women (14%). The median time from LVAD implantation to randomization was 6 months (range 5-8). Patients were followed for a median of 6 months (2-8). Twenty-five (57%) were transplanted, 12 (27%) were still on treatment, and 5 (11%) had undergone a primary outcome. Event-free survival was similar between groups (hazard ratio [HR] 1.46, 95% confidence interval [CI] 0.64-3.35, p = 0.4, Cox model) as well as Blood product use at transplantation. CONCLUSIONS: These interim results were obtained after the end of recruitment but before all patients reached the full follow-up duration. The rates of bleeding observed in the apixaban group were below those reported in large international studies without any increase in thrombosis, suggesting that apixaban 2.5 mg twice daily may offer an effective balance between bleeding risk and anticoagulation efficacy. These findings should be interpreted as preliminary and hypothesis-generating.
引用
- Schnegg B, Deveza R, Barua S, et al. Low-dose apixaban in HeartMate 3 LVAD patients, interim analysis of the ApixiVAD trial, a randomized controlled study. J Heart Lung Transplant. 2025. PMID: 40300679. doi:10.1016/j.healun.2025.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。